Interprotein Corporation - Product Pipeline Review - 2016

Published: Mar, 2016 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interprotein Corporation - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Interprotein Corporation - Product Pipeline Review - 2016', provides an overview of the Interprotein Corporation's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Interprotein Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Interprotein Corporation
- The report provides overview of Interprotein Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Interprotein Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Interprotein Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Interprotein Corporation's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Interprotein Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interprotein Corporation's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Interprotein Corporation Snapshot 5
Interprotein Corporation Overview 5
Key Information 5
Key Facts 5
Interprotein Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
Interprotein Corporation - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Interprotein Corporation - Pipeline Products Glance 14
Interprotein Corporation - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Interprotein Corporation - Drug Profiles 16
IPC-003 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Small Molecules to Inhibit VEGF for Solid Tumors 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecule to Inhibit gp130 for Inflammation and Oncology 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecule to Inhibit IgE for Allergies 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecules to Inhibit RUNX1 for Acute Myeloid Leukemia 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Synthetic Peptide to Inhibit gp130 for Inflammation and Oncology 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Synthetic Peptides to Antagonize KIR for Oncology 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Synthetic Peptides to Antagonize NKG2A for Oncology 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Synthetic Peptides to Inhibit TIM-3 for Oncology 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Interprotein Corporation - Pipeline Analysis 25
Interprotein Corporation - Pipeline Products by Target 25
Interprotein Corporation - Pipeline Products by Route of Administration 26
Interprotein Corporation - Pipeline Products by Molecule Type 27
Interprotein Corporation - Pipeline Products by Mechanism of Action 28
Interprotein Corporation - Recent Pipeline Updates 29
Interprotein Corporation - Dormant Projects 30
Interprotein Corporation - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Interprotein Corporation, Key Information 5
Interprotein Corporation, Key Facts 5
Interprotein Corporation - Pipeline by Indication, 2016 7
Interprotein Corporation - Pipeline by Stage of Development, 2016 8
Interprotein Corporation - Monotherapy Products in Pipeline, 2016 9
Interprotein Corporation - Partnered Products in Pipeline, 2016 10
Interprotein Corporation - Partnered Products/ Combination Treatment Modalities, 2016 11
Interprotein Corporation - Out-Licensed Products in Pipeline, 2016 12
Interprotein Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Interprotein Corporation - Preclinical, 2016 14
Interprotein Corporation - Discovery, 2016 15
Interprotein Corporation - Pipeline by Target, 2016 25
Interprotein Corporation - Pipeline by Route of Administration, 2016 26
Interprotein Corporation - Pipeline by Molecule Type, 2016 27
Interprotein Corporation - Pipeline Products by Mechanism of Action, 2016 28
Interprotein Corporation - Recent Pipeline Updates, 2016 29
Interprotein Corporation - Dormant Developmental Projects,2016 30
Interprotein Corporation, Other Locations 31